NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Opus Genetics, Inc. IRD
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$14.2M
▲ 29.1% vs FY2024
EPS · FY25
$-0.80
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-449.4%
Net margin · FY25
-349.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 14.2M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 349 cents on every revenue dollar this year.
Per share
USD -0.80
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-449.4%
Return on equity, FY2025
ROE
Operating margin-271.9%
Net margin-349.3%
Return on assets-113.9%
Each USD of equity lost 449 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−29.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+134.6%
Change, 10 years—
The share count grew 135% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 50.2M
total assets, end of FY2025
Total assetsUSD 50.2M
EquityUSD 15.3M
CashUSD 45.1M
Gross debtUSD 1.1M
Net debtUSD -44.0M
Current ratio6.43×
The company holds more cash than debt.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.1
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.1
−0.0
0.0
−0.0
−0.0
−0.0
·
·
·
·
−0.0
−0.0
−0.0
−0.0
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.1
−0.0
0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.80
−2.15
−0.46
0.87
−3.82
−5.28
−2.17
−5.25
−0.92
−0.43
−0.79
−0.11
−0.07
−0.06
−0.12
−0.18
−0.05
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−449.4
−203.2
−20.8
52.3
−1295.1
·
·
−190.7
−149.6
−51.9
−63.4
−94.5
−85.7
−61.5
−107.5
−183.3
−252.5
·
−463.6
Shares out B
0.07
0.03
0.02
0.02
0.02
0.01
0.00
0.00
0.03
0.02
0.20
0.18
0.15
0.12
0.10
0.08
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed